This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Collegium Pharmaceutical Names Douglas Carlson To Vice President Of Business Development

CANTON, Mass., April 3, 2013 /PRNewswire/ --  Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, has hired Douglas Carlson in the newly-created position of Vice President of Business Development.

Doug previously held the position of Senior Director, Business Development at BTG International Inc., where he was responsible for global specialty pharmaceutical M&A and licensing. Prior to BTG International, Doug spent nearly five years at Ovation Pharmaceuticals, Inc. where he advanced from Manager of Business Development to Senior Director of Corporate Business Development and Strategy, and played a pivotal role in the sale of Ovation to H. Lundbeck A/S resulting in a $900 million acquisition. Prior to Ovation, Doug was an Associate in the healthcare group at Pequot Ventures, the venture capital arm of Pequot Capital Management, Inc. Doug started his career in the healthcare investing banking group SG Cowen & Co. He received a Bachelor of Arts degree in American Studies from Trinity College in Hartford, Connecticut and completed a post-graduate advanced studies program at Oxford University.

"Collegium's lead development program, Oxycodone DETERx ®, leverages the Company's abuse-deterrent technology platform in an area with significant unmet medical need. I am incredibly excited to be joining Collegium as the Company brings its first product closer to FDA approval," states Doug Carlson.     

"As we rapidly advance Oxycodone DETERx ® towards an NDA filing within the next 12 months, we will be initiating a process to identify potential commercial partners for both the U.S. and international markets. We are excited to have a person with Doug's experience and background joining the team at this important time for the Company," states Michael Heffernan, CEO of Collegium.

About DETERx ® Technology

The DETERx ® drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide abuse-deterrent properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastronomy tube, while maintaining the extended-release properties of the product. DETERx ® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. COL-003 is the first of a number of product candidates using the DETERx ® platform.

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx ® formulation platform for the treatment of chronic pain. The DETERx ® oral drug delivery technology provides extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. For more information, visit the Company's website at


Michael Heffernan, PresidentCollegium Pharmaceutical, Inc.781.713.3699

SOURCE Collegium Pharmaceutical, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs